After setbacks, cell therapy for glioblastoma moves onto new chapter
At Penn, a leader in GBM cellular therapies since the early days of this technology, a new CAR cell therapy could find its way into clinical trials by next year in collaboration with Tmunity.
NIH, FDA and 15 private organizations join forces to increase effective gene therapies for rare diseases
NIH, FDA, 10 pharmaceutical companies and five non-profit organizations have partnered to accelerate development of gene therapies for rare diseases.
Webinar Recording: Penn at the B.PHL
The session, titled Feminine Energy: Female Founders Solving Sustainability Challenges, was a panel format featuring a Penn spinout, Pennovation tenants, and a Penn partner.
Scout Bio raises $4.75M to advance gene therapy for pets
The company has now raised more than $35 million since its inception.
Three of the top 20 highest-valued Philadelphia area startups are Penn spinouts
The Philadelphia Business Journal recently ranked the 20 highest-valued startups in Greater Philadelphia.
PCI and JPOD included in the Technical.ly Philly list of resources to boost Philly health startups
A list of Penn programs, partners and friends that work together to support new health startups in the Philadelphia region.
Former I-Corps company making breast pumping easier for moms
Adriana Vazquez spent years perfecting her breast pumping bra for company Lilu.
Interius BioTherapeutics Moves to Pennovation Lab
In October 2021, Interius BioTherapeutics (“Interius”) signed a 17,743 SF lease advancing cell and gene therapy research at the Pennovation Works innovation ecosystem.
Luxturna inventor Jean Bennett starts a new gene therapy company to tackle rare diseases left behind by pharma, VCs
Jean Bennett, who designed and co-developed Luxturna, approved in 2018 for a rare form of blindness, had kept building new gene therapies for eye diseases at her University of Pennsylvania lab.
Webinar Recording: Latest Trends in Life Science Investing
PCI hosted a webinar on Septembe 13, 2021 focused on the latest trends in the venture capital landscape. The speaker was Barbara Schilberg, Managing Director and Chief Executive Officer of BioAdvance.